$3,750.00
This report provides analyses of products, markets, and competitors in the global market for osteoporosis diagnostic products. This market, as covered by the scope of this report, includes products that are used to diagnose osteoporosis, including bone densitometry systems and bone remodeling biochemical marker tests.
This report provides analyses of products, markets, and competitors in the global market for osteoporosis diagnostic products. This market, as covered by the scope of this report, includes products that are used to diagnose osteoporosis, including bone densitometry systems and bone remodeling biochemical marker tests.
Osteoporosis is a common metabolic bone disease that is characterized by the loss of bone mineral density. The disease contributes to weakened bone tissue and a propensity for fractures, and is one of the major contributors to orthopedic injuries, especially in women. Although the disease is not restricted to women, and many factors contribute to the cause of osteoporosis, the most significant factor for women is menopause. An increase in this demographic group will play a key role in the continual demand for osteoporosis diagnostic products during the forecast period covered by this report.
In 2015, global sales of osteoporosis diagnostic products totaled approximately $253.0m; of this, bone densitometry systems accounted for $168.0m (or 66.4% of the market) and bone remodeling biochemical marker tests for $85.0m (33.6% of the market).
During the forecast period covered by this report, the value of the global market for osteoporosis diagnostic products is projected to expand at a compound annual rate of 3.8%, reaching an estimated $304.2m in 2020.
Exhibit ES-1 presents the global market forecast for osteoporosis diagnostic products during 2015-20.
Exhibit ES-2 presents estimated market share by product type for the global osteoporosis diagnostic products market for 2015.
CONTENTS
EXECUTIVE SUMMARY…………………………………………………………………………. ES-1
i. Methodology……………………………………………………………………….. ES-5
Exhibit ES-1: Global osteoporosis diagnostic products, combined market forecast, 2015-2020 ……………………………………. ES-2
Exhibit ES-2: Global osteoporosis diagnostic products market, share by product type, 2015 ………………………………………………….. ES-4
1. OVERVIEW OF OSTEOPOROSIS…………………………………………………….. 1-1
1.1 Prevalence and Cost ………………………………………………………………. 1-1
1.2 Fracture Incidence and Economic Costs ……………………………………. 1-3
1.3 Types of Osteoporosis…………………………………………………………….. 1-9
1.4 Risk Factors ………………………………………………………………………….. 1-9
1.5 Treatment ……………………………………………………………………………. 1-15
1.6 Bibliography…………………………………………………………………………. 1-16
Exhibit 1-1: Normal bone and osteoporotic bone …………………………………………. 1-2
Exhibit 1-2: Osteoporosis prevalence across the US, Japan, and 5EU, 2015-30 ………………………………………………………………………………… 1-4
Exhibit 1-3: Osteopenia prevalence across the US, Japan, and 5EU, 2015-30 ………………………………………………………………………………… 1-5
Exhibit 1-4: Osteoporosis-caused fracture incidence in the EU, by site …………… 1-6
Exhibit 1-5: US hospitalizations for fragility fractures in women, by site …………… 1-8
Exhibit 1-6: Types of osteoporosis …………………………………………………………… 1-10
Exhibit 1-7: Leading risk factors for osteoporosis ……………………………………….. 1-11
Exhibit 1-8: Population growth of 65+ years age group, 2000-50, selected countries…………………………………………………………………. 1-12
2. BONE DENSITOMETRY PRODUCTS MARKET …………………………………. 2-1
2.1 Bone Densitometry Overview …………………………………………………… 2-1
2.1.1 Dual-energy X-ray absorptiometry………………………………. 2-3
2.1.2 Single-energy X-ray absorptiometry ……………………………. 2-5
2.1.3 Radiographic absorptiometry……………………………………… 2-5
2.1.4 Quantitative computed tomography…………………………….. 2-5
2.1.5 Quantitative ultrasound …………………………………………….. 2-6
2.1.6 Software-based densitometry systems………………………… 2-6
2.1.7 Hospital-based densitometry systems…………………………. 2-9
2.1.8 Office-based densitometry systems ……………………………. 2-9
2.2 Bone Densitometry Products……………………………………………………. 2-9
2.2.1 BeamMed……………………………………………………………….. 2-9
2.2.2 CompuMed……………………………………………………………. 2-10
2.2.3 Furuno Electric Company………………………………………… 2-11
2.2.4 GE Healthcare/General Electric Company …………………. 2-11
2.2.5 Hologic …………………………………………………………………. 2-11
2.2.6 Swissray……………………………………………………………….. 2-12
2.2.7 Emerging………………………………………………………………. 2-12
2.3 Market Analysis ……………………………………………………………………. 2-21
2.3.1 Market forecast: US………………………………………………… 2-23
2.3.1.1 Insurance reimbursement………………………….. 2-24
2.3.2 Market forecast: EU………………………………………………… 2-26
2.3.2.1 DXA utilization…………………………………………. 2-28
2.3.2.2 Insurance reimbursement………………………….. 2-28
2.3.3 Market forecast: Japan……………………………………………. 2-29
2.3.4 Market forecast: rest of the world ……………………………… 2-29
2.3.5 Competitive analysis: global…………………………………….. 2-31
2.3.5.1 Competitive analysis: US ………………………….. 2-32
2.3.5.2 Competitive analysis: EU ………………………….. 2-32
2.3.5.3 Competitive analysis: rest of the world ………… 2-36
2.3.6 Detailed analysis, by competitor……………………………….. 2-36
2.3.6.1 GE Healthcare/General Electric Company …… 2-36
2.3.6.2 Hologic …………………………………………………… 2-38
2.4 Bibliography…………………………………………………………………………. 2-38
Exhibit 2-1: Comparison of biochemical markers and bone densitometr as tools for diagnosing and monitoring osteoporosis……………………. 2-2
Exhibit 2-2: Imaging modalities used to diagnose osteoporosis ……………………… 2-7
Exhibit 2-3: Selected bone densitometry systems ………………………………………. 2-13
Exhibit 2-4: BeamMed’s Sunlight Omnisense 9000 bone sonometer…………….. 2-15
Exhibit 2-5: The Norland family of dual-energy X-ray absorptiometry systems ………………………………………………… 2-16
Exhibit 2-6: GE’s Lunar iDXA dual-energy X-ray absorptiometry system ……….. 2-17
Exhibit 2-7: The Discovery and Horizon dual-energy X-ray absorptiometry systems ………………………………………………… 2-18
Exhibit 2-8: The OsteoGram radiographic absorptiometry system ………………… 2-19
Exhibit 2-9: The CM-200 quantitative ultrasound bone densitometry system….. 2-20
Exhibit 2-10: Bone densitometry systems market forecast, by region, 2015-20………………………………………………………………… 2-22
Exhibit 2-11: Spending on healthcare in the US and selected European countries ……………………………………………. 2-27
Exhibit 2-12: Bone densitometry systems global market, share by supplier, 2015 …………………………………………………………. 2-33
Exhibit 2-13: Bone densitometry systems US market, share by supplier, 2015 …………………………………………………………. 2-34
Exhibit 2-14: Bone densitometry systems EU market, share by supplier, 2015 …………………………………………………………. 2-35
Exhibit 2-15: Bone densitometry systems RoW market, share by supplier, 2015 …………………………………………………………. 2-37
3. GLOBAL MARKET FOR BONE REMODELING BIOCHEMICAL
MARKER TESTS…………………………………………………………………………….. 3-1
3.1 Biochemical Markers Overview ………………………………………………… 3-1
3.1.1 Types of bone turnover markers…………………………………. 3-2
3.1.2 Applications …………………………………………………………….. 3-2
3.1.3 Limitations ………………………………………………………………. 3-6
3.2 Biochemical Marker Testing Products ……………………………………….. 3-7
3.2.1 Alere………………………………………………………………………. 3-7
3.2.2 Beckman Coulter/Danaher ………………………………………… 3-7
3.2.3 Immunodiagnostic Systems……………………………………….. 3-7
3.2.4 Orion Diagnostica/Orion Group ………………………………….. 3-8
3.2.5 Quest Diagnostics ……………………………………………………. 3-8
3.2.6 Quidel…………………………………………………………………….. 3-8
3.2.7 Roche Diagnostics/F Hoffmann-La Roche …………………… 3-8
3.3 Reimbursement ……………………………………………………………………… 3-9
3.4 Market Analysis ……………………………………………………………………. 3-13
3.5 Competitive Analysis …………………………………………………………….. 3-14
3.5.1 Detailed analysis, by competitor……………………………….. 3-14
3.5.1.1 Alere………………………………………………………. 3-17
3.5.1.2 Quidel…………………………………………………….. 3-18
3.5.1.3 Roche Diagnostics/F Hoffmann-La Roche …… 3-18
3.6 Bibliography…………………………………………………………………………. 3-19
Exhibit 3-1: The bone remodeling cycle ……………………………………………………… 3-3
Exhibit 3-2: Comparison of selected bone remodeling biochemical marker tests…………………………………………………………. 3-4
Exhibit 3-3: Selected bone remodeling biochemical marker tests …………………. 3-10
Exhibit 3-4: Bone remodeling biochemical marker tests market forecast, by region, 2015-20………………………………………………………………… 3-15
Exhibit 3-5: Bone remodeling biochemical marker tests global market, share by supplier, 2015 …………………………………………………………. 3-16
APPENDIX: COMPANY LISTING……………………………………………………………… A-1
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!